review Open AccessTop 1% cited
BNT162b2 mRNA COVID-19 Vaccine: First Approval
Drugs · 2021 · Vol. 81(4) · pp. 495–501
Yvette N. Lamb✉(Springer Nature (New Zealand))
SARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyViral Infections and Immunology ResearchMedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Marketing authorizationPandemicAuthorization2019-20 coronavirus outbreakVirologyDiseaseOutbreak
MeSH terms
Drug DevelopmentCOVID-19SARS-CoV-2COVID-19 VaccinesmRNA VaccinesBNT162 VaccineBahrainCanadaClinical Trials as TopicEuropean UnionUnited KingdomHumansMexicoSaudi ArabiaSwitzerland
Citations
410
FWCI
21.46
field-weighted impact
References
13
Percentile
100%
vs. same field & year
Citations per year
Cited by
RNA-based therapeutics: an overview and prospectus
Cell Death and Disease · 2022 · 566 citations
References
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
New England Journal of Medicine · 2020 · 15,281 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.